STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARTV
  4. [Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Artiva Biotherapeutics (ARTV) grants RSUs and stock options to R&D president

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.

Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.

Positive

  • None.

Negative

  • None.
Insider Miralles Gines Diego
Role President & Head of R&D
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) 232,500 $0.00 --
Grant/Award Common Stock 77,500 $0.00 --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 232,500 shares (Direct, null); Common Stock — 77,500 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan. Represents stock option award granted under the Issuer's 2025 Inducement Plan. 25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months.
RSU grant 77,500 shares Restricted stock unit award under 2025 Inducement Plan
Option grant size 232,500 options Employee stock option award linked to common stock
Option exercise price $9.22 per share Strike price for employee stock options
Common shares held 77,500 shares Total common stock directly held after grants
Option holdings 232,500 options Total options directly held after grants
Initial cliff vesting date May 15, 2027 25% of option shares vest on this date
Option expiration May 17, 2036 Expiration date of the employee stock options
restricted stock unit financial
"Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Employee Stock Option (Right to Buy) financial
"Employee Stock Option (Right to Buy) with underlying common stock shares."
2025 Inducement Plan financial
"Award granted under the Issuer's 2025 Inducement Plan."
exercise price financial
"Employee stock options have a conversion or exercise price of 9.2200."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Miralles Gines Diego
(Last)(First)(Middle)
C/O ARTIVA BIOTHERAPEUTICS, INC.
5505 MOREHOUSE DRIVE, SUITE 100
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President & Head of R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026A77,500(1)A$077,500D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$9.2205/18/2026A232,500(2) (3)05/17/2036Common Stock232,500$0232,500D
Explanation of Responses:
1. Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan.
2. Represents stock option award granted under the Issuer's 2025 Inducement Plan.
3. 25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months.
/s/ Andrew Cronauer, Attorney-in-Fact05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Artiva Biotherapeutics (ARTV) grant to Diego Miralles?

Artiva Biotherapeutics granted Diego Miralles 77,500 restricted stock units and 232,500 stock options. Both awards were made under the company’s 2025 Inducement Plan, aligning his compensation more closely with shareholder value through equity-based incentives and long-term vesting.

What is the exercise price of the new Artiva Biotherapeutics (ARTV) stock options?

The new employee stock options for Diego Miralles carry an exercise price of $9.22 per share. This price is the amount he must pay to purchase each share once the options vest and become exercisable according to their specified vesting schedule.

How many Artiva Biotherapeutics (ARTV) shares does Diego Miralles hold after this Form 4?

After these grants, Diego Miralles directly holds 77,500 shares of Artiva Biotherapeutics common stock. He also holds 232,500 employee stock options linked to common shares, reflecting the equity portion of his compensation reported in this Form 4 filing.

How do the Artiva Biotherapeutics (ARTV) stock options for Diego Miralles vest?

The options vest over time: 25% of the 232,500 option shares vest on May 15, 2027. The remaining 75% then vest in equal monthly installments, at 1/36th per month, across the following 36 months, encouraging long-term employment.

What is the 2025 Inducement Plan mentioned in the Artiva Biotherapeutics (ARTV) Form 4?

The 2025 Inducement Plan is the equity plan under which these awards were granted. It provides for restricted stock units and stock options as inducement compensation, helping Artiva Biotherapeutics attract and retain key employees with performance- and tenure-based equity incentives.